Type 17 T-helper Cells Might Be a Promising Therapeutic Target for Osteoporosis.

Feng-Lai Yuan,Xia Li,Wei-Guo Lu,Yi-Qing Zhao,Cheng-Wan Li,Jian-Ping Li,Jun-Ming Sun,Rui-Sheng Xu
DOI: https://doi.org/10.1007/s11033-011-0797-z
IF: 2.7422
2011-01-01
Molecular Biology Reports
Abstract:Osteoporosis, a disease characterized by low bone mass and deterioration of bone tissue, is a pressing public health problem. Recent studies have suggested a possible role of T-helper (Th) cells in the pathogenesis of bone loss which occurs in systemic inflammatory diseases. However, there are contradictions in the published literature regarding the functional role of Th1/Th2 cells in the regulation of the differentiation of osteoclasts. These paradoxes have now been clarified by the recent discovery of Th17 cells, a novel subset of Th cells that selectively secrete several proinflammatory cytokines, mainly IL-17. It has been confirmed that Th17 cells have stimulatory effects on osteoclastogenesis and accelerate bone loss in animal models with inflammatory disorders. Targeting Th17 cells or IL-17 may inhibit the bone resorption with RA. Thus, we are led to suppose that Th17 cells might be promising therapeutic targets in osteoporosis.
What problem does this paper attempt to address?